| abstract |
A method and composition for the treatment of HIV and HBV infections innhumans is disclosed that includes administering an effective amount ofn2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceuticallynacceptable derivative thereof including a 5' or N 4 alkylated or acylated derivative,nor a pharmaceutically acceptable salt thereof in a pharmaceutically acceptablencarrier. A process for the resolution of a racemic mixture of nucleosidenenantiomers is also disclosed that includes the step of exposing the racemicnmixture to an enzyme that preferentially catalyses a reaction in one of thenenantiomers. |